Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroyuki Murai

Showing results (101-110 of 163) with videos related to

Pageof 17
Sort By:
Expert Opinion on Investigational Drugs|April 1, 2021
Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia GravisJames F Howard, John Vissing, Nils E Gilhus, et al.
Neurology|July 26, 2013
Anti-neurofascin antibody in patients with combined central and peripheral demyelinationNobutoshi Kawamura, Ryo Yamasaki, Tomomi Yonekawa, et al.
Cerebellum (London, England)|December 28, 2024
A Japanese Family with a Novel Pathogenic Variant in KIF1A Presenting with Spastic Paraparesis, Cerebellar Ataxia, and Intellectual DisabilityAkihiko Mitsutake, Mizuho Kawai, Kenta Orimo, et al.
Internal Medicine (Tokyo, Japan)|November 1, 2005
Comparison of the clinical courses of the opticospinal and conventional forms of multiple sclerosis in JapanManabu Osoegawa, Masaaki Niino, Masahito Tanaka, et al.
International Journal of Hematology|February 26, 2025
Correction: Real‑world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post‑marketing surveillance in JapanJun-Ichi Nishimura, Tatsuya Kawaguchi, Shuichi Ito, et al.
International Journal of Hematology|July 29, 2023
Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marketing surveillance in JapanJun-Ichi Nishimura, Tatsuya Kawaguchi, Shuichi Ito, et al.
Journal of the Neurological Sciences|November 18, 2004
Effect of immunotherapy in myelitis with atopic diathesisHiroyuki Murai, Hajime Arahata, Manabu Osoegawa, et al.
Journal of the Neurological Sciences|November 8, 2019
Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension studyHiroyuki Murai, Akiyuki Uzawa, Yasushi Suzuki, et al.
BMC Neurology|July 6, 2014
Quality of life in purely ocular myasthenia in JapanShigeaki Suzuki, Hiroyuki Murai, Tomihiro Imai, et al.
European Neurology|February 8, 2014
Is surgical intervention safe and effective in the treatment of myasthenic blepharoptosis? A multicenter survey in JapanYusuke Shimizu, Shigeaki Suzuki, Kimiaki Utsugisawa, et al.
Pageof 17

Showing results (101-110 of 163) with videos related to

Sort By:
Pageof 17
Expert Opinion on Investigational Drugs|April 1, 2021
Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia GravisJames F Howard, John Vissing, Nils E Gilhus, et al.
Neurology|July 26, 2013
Anti-neurofascin antibody in patients with combined central and peripheral demyelinationNobutoshi Kawamura, Ryo Yamasaki, Tomomi Yonekawa, et al.
Cerebellum (London, England)|December 28, 2024
A Japanese Family with a Novel Pathogenic Variant in KIF1A Presenting with Spastic Paraparesis, Cerebellar Ataxia, and Intellectual DisabilityAkihiko Mitsutake, Mizuho Kawai, Kenta Orimo, et al.
Internal Medicine (Tokyo, Japan)|November 1, 2005
Comparison of the clinical courses of the opticospinal and conventional forms of multiple sclerosis in JapanManabu Osoegawa, Masaaki Niino, Masahito Tanaka, et al.
International Journal of Hematology|February 26, 2025
Correction: Real‑world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post‑marketing surveillance in JapanJun-Ichi Nishimura, Tatsuya Kawaguchi, Shuichi Ito, et al.
International Journal of Hematology|July 29, 2023
Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marketing surveillance in JapanJun-Ichi Nishimura, Tatsuya Kawaguchi, Shuichi Ito, et al.
Journal of the Neurological Sciences|November 18, 2004
Effect of immunotherapy in myelitis with atopic diathesisHiroyuki Murai, Hajime Arahata, Manabu Osoegawa, et al.
Journal of the Neurological Sciences|November 8, 2019
Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension studyHiroyuki Murai, Akiyuki Uzawa, Yasushi Suzuki, et al.
BMC Neurology|July 6, 2014
Quality of life in purely ocular myasthenia in JapanShigeaki Suzuki, Hiroyuki Murai, Tomihiro Imai, et al.
European Neurology|February 8, 2014
Is surgical intervention safe and effective in the treatment of myasthenic blepharoptosis? A multicenter survey in JapanYusuke Shimizu, Shigeaki Suzuki, Kimiaki Utsugisawa, et al.
Pageof 17